Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Carolyn Anderson Short | F | 59 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
Jay Short | M | 66 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
Lawrence Steinman | M | 76 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
Richard Waldron | M | 70 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
Xiang Dong Tan | M | 69 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
Scott Smith | M | 61 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Cayman Islands | 6 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Brian Zhang
- Persönliches Netzwerk